Lindbrook Capital’s Precigen PGEN Stock Holding History

Lindbrook Capital’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.41K	Buy	+946	New	+$1.49K	﹤0.01%	2380
2024 Q3	–	Sell	-1,910	Closed	-$3.02K	–	2888
2024 Q2	$3.02K	Buy	1,910 +268	+16%	+$389	﹤0.01%	2216
2024 Q1	$2.38K	Hold	1,642	–	–	﹤0.01%	2178
2023 Q4	$2.2K	Buy	+1,642	New	+$1.93K	﹤0.01%	2223
2022 Q4	–	Sell	-1,771	Closed	-$3.05K	–	2967
2022 Q3	$4K	Buy	1,771 +812	+85%	+$1.71K	﹤0.01%	1784
2022 Q2	$1K	Buy	+959	New	+$1.42K	﹤0.01%	2326
2022 Q1	–	Sell	-754	Closed	-$3K	–	2584
2021 Q4	$3K	Buy	754 +216	+40%	+$930	﹤0.01%	1690
2021 Q3	$3K	Hold	538	–	–	﹤0.01%	1433
2021 Q2	$4K	Hold	538	–	–	﹤0.01%	1387
2021 Q1	$4K	Sell	538 -100	-16%	-$845	﹤0.01%	1348
2020 Q4	$7K	Buy	638 +100	+19%	+$648	﹤0.01%	1058
2020 Q3	$2K	Hold	538	–	–	﹤0.01%	1426
2020 Q2	$3K	Buy	+538	New	+$1.83K	﹤0.01%	1287

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Lindbrook Capital's PGEN Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Precigen (PGEN) in Q1 2025: 946 shares worth $1.41K. The stake represents ﹤0.01% of the portfolio and ranks #2380 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in PGEN as recently as Q2 2024.

Lindbrook Capital first reported a position in PGEN in Q2 2020 and has held it in 13 quarters since. The position peaked at $7K in Q4 2020. 138 funds tracked by Wall St. Rank hold PGEN as of Q1 2025.

Lindbrook Capital held 946 shares of Precigen worth $1.41K as of Q1 2025.
Precigen was a new Lindbrook Capital position in Q1 2025.
Precigen made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2380 holding.
Lindbrook Capital first reported a position in Precigen in Q2 2020 and has held it in 13 quarters since.
Lindbrook Capital's Precigen position peaked at $7K in Q4 2020.
138 funds tracked by Wall St. Rank held Precigen as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.